Mumps in seat 21C!

As SARS emerged in 2003, attention quickly turned to airplanes, the most likely source of international spread. At the time, the US Centers for Disease Control and Prevention (CDC) received passenger manifests, usually in hard copy, to notify people who had shared a flight with someone later diagnosed with the infection.In the Internet age, that procedure was hardly ideal. "The paper management of data was problematic," says the CDC's Christie Reed, mainly because of the di

Written byMelissa Lee Phillips
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

As SARS emerged in 2003, attention quickly turned to airplanes, the most likely source of international spread. At the time, the US Centers for Disease Control and Prevention (CDC) received passenger manifests, usually in hard copy, to notify people who had shared a flight with someone later diagnosed with the infection.

In the Internet age, that procedure was hardly ideal. "The paper management of data was problematic," says the CDC's Christie Reed, mainly because of the difficulty of sharing information with other health officials across the country. When the CDC's actions in response to SARS were later evaluated, "there was a recommendation that we develop a better, more rapid system to notify persons who may have had exposure," Reed says.

That's when CDC scientists began to work on eManifest, an in-house CDC database that imports electronic passenger data that the airlines give to the CDC, says Nancy Gallagher, a CDC ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies